Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
BerGenBio completes $8.8M Series A financing round

BerGenBio completes $8.8M Series A financing round

Ipswitch announces lead sponsorship for Annual Resolution Run to Kick Cancer 5k Road Race

Ipswitch announces lead sponsorship for Annual Resolution Run to Kick Cancer 5k Road Race

AccuGenomics to participate in OneMedForum at Sir Francis Drake hotel

AccuGenomics to participate in OneMedForum at Sir Francis Drake hotel

TrovaGene enters definitive agreement to acquire MultiGEN

TrovaGene enters definitive agreement to acquire MultiGEN

TrovaGene acquires license to mutations of SF3B1 splicing factor in CLL

TrovaGene acquires license to mutations of SF3B1 splicing factor in CLL

Emergent commences Phase 2 combination trial of TRUw-016 with bendamustine in relapsed CLL

Emergent commences Phase 2 combination trial of TRUw-016 with bendamustine in relapsed CLL

Study linking chronic fatigue syndrome with virus infection retracted

Study linking chronic fatigue syndrome with virus infection retracted

Obama and Gingrich differ on embryonic stem cell research

Obama and Gingrich differ on embryonic stem cell research

Scientific journal retracts study that linked mouse virus to human chronic fatigue syndrome

Scientific journal retracts study that linked mouse virus to human chronic fatigue syndrome

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

D12-PGJ3 compound can cure leukemia

D12-PGJ3 compound can cure leukemia

EpiCept receives FDA approval to commence AmiKet Phase III trial for CIPN

EpiCept receives FDA approval to commence AmiKet Phase III trial for CIPN

UCB initiates EXXELERATE study in rheumatoid arthritis

UCB initiates EXXELERATE study in rheumatoid arthritis

Cancer-causing potential of fetal exposure to carcinogens can vary substantially

Cancer-causing potential of fetal exposure to carcinogens can vary substantially

Scientists discover gene that causes Weaver syndrome

Scientists discover gene that causes Weaver syndrome

Scientists uncover critical genetic mutation in patients with MDS

Scientists uncover critical genetic mutation in patients with MDS

Novel prognostic model for patients with treatment-related MDS

Novel prognostic model for patients with treatment-related MDS

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Maraviroc reduces incidence of GvHD in blood cancer patients after ASCT

Maraviroc reduces incidence of GvHD in blood cancer patients after ASCT

Promising results from Fate Therapeutics' ProHema Phase 1b trial on hematologic malignancies

Promising results from Fate Therapeutics' ProHema Phase 1b trial on hematologic malignancies

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.